MAYNE PHARMA GROUP LIMITED — M&A Activity 2013

Jan 31, 2013

==> picture [115 x 58] intentionally omitted <==

1 February 2013

KAPANOL ® ACQUISITION COMPLETED

Mayne Pharma Group Limited (Mayne Pharma; ASX: MYX) is pleased to announce the completion of the acquisition of Kapanol® and related assets in Australia from GlaxoSmithKline. The acquisition, announced on 14 December 2012, was funded by an underwritten placement to institutional and sophisticated investors, which was heavily oversubscribed.

Mayne Pharma CEO Mr Scott Richards said, “The acquisition of Kapanol® represents a natural bolt-on opportunity for Mayne Pharma enabling us to now market and distribute in Australia this well-established oral opioid analgesic used for the relief of chronic, moderate to severe pain. We have begun recruitment of a national sales team to reinvigorate sales of Kapanol® and promote our other domestic products such as Astrix®, Doryx®, Eryc® and any future products that are developed, in-licensed or acquired. Since announcing this acquisition, we have been delighted by the positive feedback received from a number of key opinion leaders that Mayne Pharma has chosen to reinvest in its Australian developed and manufactured pain management product.”

-ENDS-

For further information contact:

Scott Richards +61 8 8209 2410 Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com